The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study
Open accessAbstract
Background Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is limited by bleeding concerns. Asundexian, a novel, oral small molecule activated coagulation factor XIa (FXIa) inhibitor, might reduce thrombosis with minimal effect on haemostasis. We aimed to determine the optimal dose of asundexian and to compare the incidence of bleeding with that of apixaban in patients with atrial fibrillation. Methods In this randomised, double-blind, phase 2 dose-finding study, we compared asundexian 20 mg or 50 mg once daily with apixaban 5 mg twice daily in patients aged 45 years or older with atrial fibrillation, a CHA 2 DS 2 -VASc score of at least 2 if male or at least 3 if female, and increased bleeding risk. The study was conducted at 93 sites in 14 countries, including 12 European countries, Canada, and Japan. Participants were randomly assigned (1:1:1) to a treatment group using an interactive web response system, with randomisation stratified by whether patients were receiving a direct-acting oral anticoagulant before the study start. Masking was achieved using a double-dummy design, with participants receiving both the assigned treatment and a placebo that resembled the non-assigned treatment. The primary endpoint was the composite of major or clinically relevant non-major bleeding according to International Society on Thrombosis and Haemostasis criteria, assessed in all patients who took at least one dose of study medication. This trial is registered with ClinicalTrials.gov, NCT04218266, and EudraCT, 2019-002365-35. Findings Between Jan 30, 2020, and June 21, 2021, 862 patients were enrolled. 755 patients were randomly assigned to treatment. Two patients (assigned to asundexian 20 mg) never took any study medication, resulting in 753 patients being included in the analysis (249 received asundexian 20 mg, 254 received asundexian 50 g, and 250 received apixaban). The mean age of participants was 73·7 years (SD 8·3), 309 (41%) were women, 216 (29%) had chronic kidney disease, and mean CHA 2 DS 2 -VASc score was 3·9 (1·3). Asundexian 20 mg resulted in 81% inhibition of FXIa activity at trough concentrations and 90% inhibition at peak concentrations; asundexian 50 mg resulted in 92% inhibition at trough concentrations and 94% inhibition at peak concentrations. Ratios of incidence proportions for the primary endpoint were 0·50 (90% CI 0·14–1·68) for asundexian 20 mg (three events), 0·16 (0·01–0·99) for asundexian 50 mg (one event), and 0·33 (0·09–0·97) for pooled asundexian (four events) versus apixaban (six events). The rate of any adverse event occurring was similar in the three treatment groups: 118 (47%) with asundexian 20 mg, 120 (47%) with asundexian 50 mg, and 122 (49%) with apixaban. Interpretation The FXIa inhibitor asundexian at doses of 20 mg and 50 mg once daily resulted in lower rates of bleeding compared with standard dosing of apixaban, with near-complete in-vivo FXIa inhibition, in patients with atrial fibrillation. Funding Bayer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 9,971
Self-citationApixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study
Chugh, S. S., Havmoeller, R., Narayanan, K., Singh, D., Rienstra, M., Benjamin, E. J., Gillum, R. F., Kim, Y.-H., McAnulty, J. H., Zheng, Z.-J., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005119 · Cited by 4,506
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.011 · Cited by 2,205
Antithrombotic Therapy for Atrial Fibrillation
Lip, G. Y. H., Banerjee, A., Boriani, G., Chiang, C. E., Fargo, R., Freedman, B., Lane, D. A., Ruff, C. T., Turakhia, M., Werring, D., et al. (2018) · Chest · doi:10.1016/j.chest.2018.07.040 · Cited by 939
Self-citationFactor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Büller, H. R., Bethune, C., Bhanot, S., Gailani, D., Monia, B. P., Raskob, G. E., Segers, A., Verhamme, P., & Weitz, J. I. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405760 · Cited by 630
Self-citationFactor XI Deficiency in Ashkenazi Jews in Israel
Asakai, R., Chung, D. W., Davie, E. W., & Seligsohn, U. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107183250303 · Cited by 383
Milvexian for the Prevention of Venous Thromboembolism
Weitz, J. I., Strony, J., Ageno, W., Gailani, D., Hylek, E. M., Lassen, M. R., Mahaffey, K. W., Notani, R. S., Roberts, R., Segers, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113194 · Cited by 269
Cited by
Van Gelder, I. C., Rienstra, M., Bunting, K. V., Casado-Arroyo, R., Caso, V., Crijns, H. J. G. M., De Potter, T. J. R., Dwight, J., Guasti, L., Hanke, T., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae176 · Cited by 3,024
Self-citation
Metadata
- Authors
- Piccini, J. P., Caso, V., Connolly, S. J., Fox, K. A. A., Oldgren, J., Jones, W. S., Gorog, D. A., Durdil, V., Viethen, T., Neumann, C., Mundl, H., Patel, M. R., Auer, J., Hubauer, M., Pandzic, S., Preishuber, E., Primus-Grabscheit, C., Reitgruber, D., Schmalzer, F., Adlbrecht, C., Schober, A., Hajos, J., Keil, C., Schratter, A., Frick, M., Benda, M. A., Mächler, M., Mutschlechner, B., Saely, C., Sprenger, L., Lichtenauer, M., Eber, M., Hoppe, U., Kolbitsch, T., Jirak, P. M., Mirna, M., Schönbauer, R., Bergler-Klein, J., Hengstenberg, C., Stojkovic, S., Scherr, D., Manninger-Wünscher, M., Rohrer, U., Stühlinger, M., Schgoer, W., Schwarzl, J., Pürerfellner, H., Derndorfer, M., Ebner, C., Eder, V., Kollias, G., Sturmberger, T., Sieghartsleitner, S., Vijgen, J., Koopman, P., Dujardin, K., Anné, W., De Ceuninck, M., Tavernier, R., Duytschaever, M., Knecht, S., Missault, L., Vandekerckhove, Y., Rossenbacker, T., Ector, B., Charlier, F., Debruyne, P., Dewilde, W., Janssens, L., Roosen, J., Vankelecom, B., Heidbuchel, H., Delesie, M., Vervoort, G., Rombouts, H., Vanassche, T., Engelen, M., Verhamme, P., Willems, R., Constance, C., Pranno, N., Cox, J., Bata, I., Macle, L., Aguilar, M., Tourigny, J. C., Dubuc, M., Dyrda, K., Guerra, P., Khairy, P., Mondésert, B., Rivard, L., Roy, D., Tadros, R., Talajic, M., Thibault, B., Nault, I., Blier, L., Champagne, J., Molin, F., O'Hara, G., Philippon, F., Plourde, B., Sarrazin, J.-F., Steinberg, C., Coufal, Z., Balazsik, D., Mikulica, M., Zapeca, J., Cermak, O., Drasnar, T., Falc, M., Hornof, J., Racz, B., Weissova, D., Linkova, H., Paskova, E., Petr, R., Sirakova, A., Kettner, J., Benak, A., Holek, M., Podpera, I., Podperova, M., Vancura, V., Jandik, T., Smid, J., Dedek, V., Banik, J., Durdil, V., Hnat, T., Lellouche, N., Rouffiac, S., Taldir, G., Bridonneau, V., Couffon, P., Daudin, M., Hamon, C., Lacaze, J., Quentin, A., Thebault, C., Boiffard, E., Billon, O., Miette, F., Pouliquen, H., Turlotte, G., Gorka, H., Albert, F., Bayle, S., Bensaid, R., Dasoveanu, M., Demichili, T., Dutoiu, T., Khalil, C., Loghin, C., Range, G., Roussel, L., Socié, P., Thuaire, C., Extramiana, F., Algalarrondo, V., Boughanmi, H., El Mansour, N., Mohammad, U., Sellier, R., Elbaz, M., Laperche, C., Maury, P., Kiss, R., Borsanyi, T., Gingl, Z., Polgar, B., Benczur, B., Bodor, A., Hepp, T., Malati, E., Nagy, L., Erdei, N., Kapus, J., Kapus, K., Toth, B., Matoltsy, A., Kiss, T., Merkely, B., Herczeg, S., Kiss, O., Sallo, Z., Toth, K., Habon, T., Rabai, M., Totsimon, K., Zilahi, Z., Bencze, G., Santa, J., Aradi, D., Kelemen, B., Bolognese, L., Nesti, M., Notarstefano, P. G., D'Orazio, S., Cosmi, F., Becattini, C., Agnelli, G., Broccatelli, B., Mosconi, M. G., Paciaroni, M., Urbini, C., Parato, V. M., Notaristefani, C., Scarano, M., Ameri, P., Ghigliotti, G., Guglielmi, G., Lotti, R., Merlo, A. C., Muiesan, M. L., Abondio, A., Berasi, C., Mattiuzzo, E., Mutti, C., Salvetti, M., Pignatelli, P., Menichelli, D., Pastori, D., Tamiya, E., Matsumoto, T., Takabe, T., Yamamoto, S., Yamashita, H., Higashiue, S., Furuya, O., Hiramatsu, N., Kasuga, K., Kojima, S., Komooka, M., Kuroyanagi, S., Matsuura, M., Takemoto, T., Yamamoto, S., Saito, K., Abe, T., Ishida, I., Iwanami, Y., Kataoka, S., Moriyama, T., Murohashi, A., Sasaki, A., Nakamura, Y., Ueno, T., Shimane, A., Hamana, T., Ichibori, H., Inoue, T., Itoh, M., Iwane, S., Kawai, H., Kokawa, T., Masumoto, A., Matsuo, K., Miyata, T., Nakano, S., Oishi, S., Onishi, T., Sawada, T., Saito, T., Shoda, M., Takahashi, N., Takaya, T., Taniguchi, Y., Tsukamoto, S., Tsukishiro, Y., Tsukiyama, Y., Tsunamoto, H., Uzu, K., Yamamoto, H., Yamamoto, T., Yokoi, K., Yoshida, C., Watanabe, N., Betsuyaku, T., Adachi, K., Awane, K., Goto, D., Sakakibara, M., Watanabe, M., Ueno, H., Hiroe, Y., Matsuo, K., Ayata, K., Fukuda, K., Hata, Y., Hashimoto, K., Matsumi, H., Nikaido, A., Okamoto, S., Sime, I., Stirna, V., Reinholde, I., Hansone, S., Kozlovska, A., Romanova, J., Klincare, D., Pontaga, N., Dirmans, I., Kalnins, A., Upite, D., Gersamija, A., Teleznikovs, A., Rozkova, N., Safro, J., Anguera Camós, I., Domenico Dallaglio, P., Salguero Bodes, R., Arnbas, F., Borrego, L., Marco, A., Jimenez, J. R., Gómez-Doblas, J. J., Pérez Cabeza, A., Ferreira Gonzålez, I., Limeres Freire, J., Lopez Grau, M., Viñolas Prat, X., Moreno Weidmann, Z., Guerra Ramos, J. M., Alonso Martin, M. C., Campos Garcia, B., Mogro Carranza, J. M., Mendez Zurita, F. J., Rodriguez Font, E., Gonzales Matos, C. E., García Hernando, V., Lindholm, C.-J., Thulin, J., Wallén, H., Hagwall, K., Eliasson, K., Lundvall, M., Olsson, J., Kjellman, B., Lind, M., Johansson, L., Svedberg, N., Berglund, S., Söderberg, J., Zedigh, C., Mooe, T., Axelsson, M., Binsell, E., Huber, D., Müller, C., Danier, I., Kühne, M., Okamura, B., Schoepfer, H., Simmen, C., Reichlin, T., Chollet, L., Lam, A., Wittmer, S., Rickli, H., Gall, C., Hametner, G., Intorp, S., Luescher, D., Haegeli, L., Berg, J. C., Ebrahimi, R., Auricchio, A., Crljenica, C., Moccetti, T., Monti, C., Pasotti, E., Petrova, I., Rossi, M., Mach, F., Namdar, M., de Groot, J., Proost, V., Neefs, J., Linz, D., van Stipdonk, T., den Uijl, D., Alings, M., Schaap, J., Segers, D., Wouters, N., Bartels, L., Tieleman, R., Pisters, R., de Vries, T., Selig, J., Kuijper, A., Bot, P., Keijzers, M., Verdel, G., Tukkie, R., van den Bos, E., Kauer, F., Oemrawsingh, R., Stevenhagen, J., van Es, J., Lip, G., Gupta, D., Kotalczyk, A., Gunstone, A., Brixey, R. D., Gorog, D., Dinarvand, D., Gue, Y., Kanji, R., Memtsas, V., Senior, R., Bioh, G., Wong, Y.-K., & Child, N.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-04
- Volume
- 399
- Issue
- 10333
- Pages
- 1383-1390
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4223439574
- Cited by
- 323
- References
- 18
- FWCI
- 44.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. https://app.cochat.ai/papers/10.1016/s0140-6736(22)00456-1
- The paper
- Piccini, J. P., Caso, V., Connolly, S. J., Fox, K. A. A., Oldgren, J., Jones, W. S., Gorog, D. A., Durdil, V., Viethen, T., Neumann, C., Mundl, H., Patel, M. R., Auer, J., Hubauer, M., Pandzic, S., Preishuber, E., Primus-Grabscheit, C., Reitgruber, D., Schmalzer, F., . . . Child, N. (2022). Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. The Lancet. https://doi.org/10.1016/s0140-6736(22)00456-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.